BR112017009263A2 - antibody or fragment thereof that binds to a human cd38, bispecific antibody, antibody or fragment thereof that binds to human and cinomolgous cd38, soluble human cd38 epitope, composition and immunoconjugate - Google Patents

antibody or fragment thereof that binds to a human cd38, bispecific antibody, antibody or fragment thereof that binds to human and cinomolgous cd38, soluble human cd38 epitope, composition and immunoconjugate

Info

Publication number
BR112017009263A2
BR112017009263A2 BR112017009263-8A BR112017009263A BR112017009263A2 BR 112017009263 A2 BR112017009263 A2 BR 112017009263A2 BR 112017009263 A BR112017009263 A BR 112017009263A BR 112017009263 A2 BR112017009263 A2 BR 112017009263A2
Authority
BR
Brazil
Prior art keywords
human
antibody
binds
fragment
cinomolgous
Prior art date
Application number
BR112017009263-8A
Other languages
Portuguese (pt)
Inventor
Ollier Romain
Hou Samuel
Lissilaa Rami
Skegro Darko
Back Jonathan
Original Assignee
Glenmark Pharmaceuticals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2014/073738 external-priority patent/WO2015063339A1/en
Application filed by Glenmark Pharmaceuticals S.A. filed Critical Glenmark Pharmaceuticals S.A.
Publication of BR112017009263A2 publication Critical patent/BR112017009263A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se às imunoglobulinas hetero-diméricas que marcam ambos, um componente do antígeno cd3 humano e um componente do antígeno cd38 humano e métodos para preparar os mesmos. a presente invenção também se refere aos anticorpos que se ligam ao antígeno cd38 humano e aos derivados dos mesmos para uso como terapêutico ou reagente de diagnóstico e métodos para preparar o mesmo.The present invention relates to hetero-dimeric immunoglobulins which both mark a component of human cd3 antigen and a component of human cd38 antigen and methods for preparing them. The present invention also relates to antibodies which bind to human cd38 antigen and derivatives thereof for use as a therapeutic or diagnostic reagent and methods for preparing the same.

BR112017009263-8A 2014-11-04 2015-11-03 antibody or fragment thereof that binds to a human cd38, bispecific antibody, antibody or fragment thereof that binds to human and cinomolgous cd38, soluble human cd38 epitope, composition and immunoconjugate BR112017009263A2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2014/073738 WO2015063339A1 (en) 2013-11-04 2014-11-04 Production of t cell retargeting hetero-dimeric immunoglobulins
EPPCT/EP2014/073738 2014-11-04
EP15167034.6 2015-05-08
EP15167034 2015-05-08
PCT/EP2015/075628 WO2016071355A1 (en) 2014-11-04 2015-11-03 Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production

Publications (1)

Publication Number Publication Date
BR112017009263A2 true BR112017009263A2 (en) 2018-01-30

Family

ID=53059011

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017009263-8A BR112017009263A2 (en) 2014-11-04 2015-11-03 antibody or fragment thereof that binds to a human cd38, bispecific antibody, antibody or fragment thereof that binds to human and cinomolgous cd38, soluble human cd38 epitope, composition and immunoconjugate

Country Status (20)

Country Link
EP (1) EP3215541A1 (en)
JP (3) JP2018501297A (en)
KR (1) KR20170078831A (en)
CN (1) CN107207596A (en)
AU (1) AU2015341884B2 (en)
BR (1) BR112017009263A2 (en)
CA (1) CA2965745C (en)
CL (1) CL2017001090A1 (en)
CO (1) CO2017005240A2 (en)
EA (1) EA039658B1 (en)
HK (1) HK1244014A1 (en)
IL (1) IL251848A0 (en)
MA (1) MA40894A (en)
MX (1) MX2017005814A (en)
MY (1) MY186929A (en)
NZ (1) NZ732019A (en)
PE (1) PE20171041A1 (en)
PH (1) PH12017500819A1 (en)
SG (1) SG11201703313SA (en)
WO (1) WO2016071355A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
EP2943511B1 (en) 2013-01-14 2019-08-07 Xencor, Inc. Novel heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
CA2918795A1 (en) 2013-07-25 2015-01-29 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
US9493563B2 (en) 2013-11-04 2016-11-15 Glenmark Pharmaceuticals S.A. Production of T cell retargeting hetero-dimeric immunoglobulins
SG10202008629XA (en) 2014-03-28 2020-10-29 Xencor Inc Bispecific antibodies that bind to cd38 and cd3
CN107108738A (en) 2014-07-25 2017-08-29 西托姆克斯治疗公司 Anti-cd 3 antibodies, it anti-cd 3 antibodies, polyspecific anti-cd 3 antibodies, polyspecific can be activated can activate anti-cd 3 antibodies and its application method
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
IL252480B2 (en) 2014-11-26 2023-12-01 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens
JP2017536830A (en) 2014-11-26 2017-12-14 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Heterodimeric antibodies that bind to CD3 and CD38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
TWI796283B (en) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Antibody constructs for msln and cd3
TWI829617B (en) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Antibody constructs for flt3 and cd3
US11623957B2 (en) 2015-12-07 2023-04-11 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
EA039859B1 (en) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Bispecific antibody constructs binding egfrviii and cd3
IL263542B1 (en) 2016-06-14 2024-06-01 Xencor Inc Bispecific checkpoint inhibitor antibodies
EA201992143A1 (en) * 2017-04-24 2020-03-13 Икнос Сайенсиз Са B-SPECIFIC ANTIBODIES REDIRECTING T-CELLS TO TREAT EGFR-POSITIVE CANCER DISEASES
MA49250A (en) 2017-06-05 2021-04-14 Numab Therapeutics AG NEW ANTI-CD3 ANTIBODIES
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
CA3066553A1 (en) * 2017-06-08 2018-12-13 Black Belt Therapeutics Limited Cd38 modulating antibody
CN111051344B (en) 2017-06-08 2023-10-27 黑带医疗有限公司 CD38 modulating antibodies
KR20240015159A (en) * 2017-08-10 2024-02-02 그리폴스 다이어그노스틱 솔루션즈 인크. Compositions, methods and/or kits comprising a recombinant human cd38-extracellular domain
US11542338B2 (en) 2017-08-16 2023-01-03 Black Belt Therapeutics Limited CD38 modulating antibody
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Multispecific molecules that bind to bcma and uses thereof
EP3668543A1 (en) 2017-08-16 2020-06-24 Black Belt Therapeutics Limited Cd38 antibody
WO2019075405A1 (en) 2017-10-14 2019-04-18 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
KR20210075101A (en) * 2018-09-25 2021-06-22 아이크노스 사이언스 에스. 아. Antibody quantification in biological samples
KR102353568B1 (en) * 2018-11-14 2022-01-20 주식회사 헬릭스미스 Anti c-Met Antibody or Antigen binding fragment thereof with Improved Stability
BR112021014574A2 (en) 2019-01-23 2021-10-05 Encefa CD31 COMPETITORS AND USES THEREOF
US20220177582A1 (en) * 2019-03-13 2022-06-09 Ichnos Sciences SA Non-consensus glycosylation of bispecific antibodies
WO2020237173A1 (en) * 2019-05-23 2020-11-26 VelosBio Inc. Anti-ror1/anti-cd3 bispecific binding molecules
WO2020250940A1 (en) * 2019-06-11 2020-12-17 小野薬品工業株式会社 Immunosuppression agent
CN110551222B (en) * 2019-08-27 2023-06-06 重庆市畜牧科学院 Novel bifunctional antibody and application thereof
KR20220071263A (en) * 2019-09-30 2022-05-31 하버 바이오메드 (쑤저우) 컴퍼니 리미티드 Antibodies targeting CD3, bispecific antibodies and uses thereof
CN113493519B (en) * 2020-03-19 2022-12-27 浙江道尔生物科技有限公司 Fusion protein with remarkably prolonged half-life for treating ocular angiogenesis diseases
CN115803340A (en) * 2020-04-24 2023-03-14 纪念斯隆凯特琳癌症中心 anti-CD 3 antibodies and uses thereof
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
CA3180690A1 (en) * 2020-06-17 2021-12-23 Ahmed Mahiuddin Cd38 antibodies for treatment of human diseases
IL300666A (en) 2020-08-19 2023-04-01 Xencor Inc Anti-cd28 compositions
JP2024509274A (en) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Heterodimeric antibody that binds to CD3 and GPC3

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008504013A (en) * 2004-02-06 2008-02-14 モルフォシス・アクチェンゲゼルシャフト Anti-CD38 human antibody and use thereof
ES2716874T3 (en) * 2005-03-23 2019-06-17 Genmab As Antibodies against cd38 for the treatment of multiple myeloma
EP1945671A2 (en) * 2005-10-12 2008-07-23 MorphoSys AG Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CN102471378B (en) * 2009-06-26 2014-04-02 瑞泽恩制药公司 Readily isolated bispecific antibodies with native immuneoglobulin format
MX2012007497A (en) * 2009-12-25 2012-08-01 Chugai Pharmaceutical Co Ltd Polypeptide modification method for purifying polypeptide multimers.
EP2580243B1 (en) * 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
JOP20210044A1 (en) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-cd38 antibodies
SG10201602371VA (en) * 2011-03-25 2016-04-28 Glenmark Pharmaceuticals Sa Hetero-dimeric immunoglobulins
KR20150076172A (en) * 2012-09-25 2015-07-06 그렌마크 파머수티칼스 에스. 아. Purification of Hetero-dimeric Immunoglobulins
EP2914302B1 (en) * 2012-11-05 2017-01-04 MorphoSys AG Radiolabelled antibody and uses thereof
US9493563B2 (en) * 2013-11-04 2016-11-15 Glenmark Pharmaceuticals S.A. Production of T cell retargeting hetero-dimeric immunoglobulins

Also Published As

Publication number Publication date
IL251848A0 (en) 2017-06-29
JP2019214582A (en) 2019-12-19
CO2017005240A2 (en) 2017-10-31
EA039658B1 (en) 2022-02-22
CA2965745A1 (en) 2016-05-12
HK1244014A1 (en) 2018-07-27
MX2017005814A (en) 2017-08-02
JP2018501297A (en) 2018-01-18
KR20170078831A (en) 2017-07-07
JP7403505B2 (en) 2023-12-22
CN107207596A (en) 2017-09-26
JP2021184722A (en) 2021-12-09
CA2965745C (en) 2023-12-05
CL2017001090A1 (en) 2018-01-05
SG11201703313SA (en) 2017-05-30
EA201790961A1 (en) 2017-10-31
MA40894A (en) 2017-09-12
EP3215541A1 (en) 2017-09-13
PH12017500819A1 (en) 2017-10-02
AU2015341884A1 (en) 2017-06-08
MY186929A (en) 2021-08-26
PE20171041A1 (en) 2017-07-19
AU2015341884B2 (en) 2020-09-17
NZ732019A (en) 2022-07-29
WO2016071355A1 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
BR112017009263A2 (en) antibody or fragment thereof that binds to a human cd38, bispecific antibody, antibody or fragment thereof that binds to human and cinomolgous cd38, soluble human cd38 epitope, composition and immunoconjugate
BR112018000696A2 (en) antibody, methods for reducing and increasing the binding affinity of a human cd3 binding antibody, for treating and diagnosing a disease, for producing an antibody, and for detecting the presence of cd3 antigen, nucleic acid construct, expression vector, host cell, composition, and kit?
BR112018016697A2 (en) coated, chimeric or humanized antibody, pharmaceutical composition, and method of treatment.
BR112016022910A2 (en) bispecific her2 antibodies
BR112018071307A2 (en) human cd40 binding agonist antibodies and uses thereof
BR112017003194B8 (en) ANTIBODY OR ANTIGEN-BINDING FRAGMENT OF THE SAME THAT SPECIFICALLY BINDS TO HUMAN LAG3, COMPOSITION, AND, USE OF THE ANTIBODY OR AN ANTIGEN-BINDING FRAGMENT OF THESE AND THE COMPOSITION
BR112017027778A2 (en) factor xi antibodies and methods of use
BR112018001374A2 (en) Bispecific antibody constructs that bind to egfrviii and cd3
BR112016025056A2 (en) use of at least one polypeptide, bispecific antibody, isolated bispecific antibody, her3 / her2 bispecific antibody, host cell, her3 / her2 bispecific antibody production method, immunoconjugate and pharmaceutical formulation
BR112018067522A2 (en) human poliovirus receptor (pvr) specific antibodies
BR112017025693A2 (en) anti-cd40 antibodies and their uses
BR112018004733A2 (en) Bispecific human / a-beta transferrin receptor antibodies and methods of use
BR112014018481A2 (en) monoclonal or polyclonal antibody or antigen-binding fragment thereof, polynucleotide, monoclonal antibody, vector, hybridoma, antibody, hybridoma 5166-2 and / or 5166-9, antigen-binding antibody or fragment, pharmaceutical composition, antibody use or antibody binding fragment, method for treating cancer, method for diagnosing cancer in an individual, antibody, method, composition or use
CR20170200A (en) ANTIBODY-FARMACO CONJUGATES
BR112017025080A2 (en) anti-cd123 antibody drug conjugated compound, antibody drug conjugated composition, method of treating a patient having a cd123 expressing cancer, pharmaceutical composition, and intact antibody or antigen binding fragment
BR112016022841A8 (en) IGM, IGA, IGG / IGM OR IGG / IGA ANTIBODY, OR AN ANTIGEN-BINDING FRAGMENT THEREOF, COMPOSITION WHICH COMPRISES IT AND USE THEREOF
BR112015007672A2 (en) human monoclonal anti-pd-l1 antibodies and methods of use
BR112014027291A2 (en) humanized pan-her antibody compositions
BR112017012954A2 (en) antibody compositions and methods targeting bmp6
UY37591A (en) ANTIBODY DRUG CONJUGATES
BR112017014771A2 (en) antibody, polynucleotide, expression unit, host cell, methods for producing an antibody and for treating an individual, composition, use of an antibody in a diagnostic method, and expression vector
BR112016014731A2 (en) ANTI-BAFF ANTIBODIES
BR112019010595A2 (en) antibody or antigen binding fragment thereof, combination of isolated nucleic acid molecules, pharmaceutical composition, kit, and method for selecting a compound.
BR112018070948A2 (en) anti-psma antibodies and their use
UY36942A (en) ANTIGEN UNION PROTEINS THAT ACTIVATE THE LEPTINE RECEIVER

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25D Requested change of name of applicant approved

Owner name: ICHNOS SCIENCES SA (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]